Table 1:
Quarterly age-standardized incidence rates per million among Canadian children younger than 15 years of age who had a new diagnosis of cancer between December 2017 and November 2020
| Parameter | Baseline period ASIR | COVID-19 pandemic ASIR | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|||||||||||
| December 2017–February 2018 | March–May 2018 | June–August 2018 | September–November 2018 | December 2018–February 2019 | March–May 2019 | June–August 2019 | September–November 2019 | December 2019–February 2020 | March–May 2020 | June–August 2020 | September–November 2020 | |
| All cancers combined | 166.9 | 158.4 | 155.6 | 173.5 | 156.4 | 175.1 | 170.6 | 150.3 | 153.0 | 157.7 | 164.6 | 148.0 |
|
| ||||||||||||
| Sex | ||||||||||||
|
| ||||||||||||
| Male | 179.7 | 166.8 | 173.7 | 189.5 | 172.9 | 183.7 | 188.2 | 159.9 | 163.4 | 167.7 | 194.1 | 151.6 |
|
| ||||||||||||
| Female | 153.5 | 149.5 | 136.6 | 156.8 | 139.2 | 166.2 | 152.5 | 140.2 | 142.1 | 147.2 | 133.5 | 144.1 |
|
| ||||||||||||
| Age, yr | ||||||||||||
|
| ||||||||||||
| < 1 | 262.8 | 265.0 | 297.2 | 325.8 | 230.8 | 338.1 | 203.5 | 221.7 | 321.5 | 312.9 | 309.0 | 253.9 |
|
| ||||||||||||
| 1–4 | 225.2 | 220.1 | 184.1 | 217.4 | 222.7 | 233.1 | 258.9 | 210.2 | 199.7 | 228.1 | 242.7 | 217.6 |
|
| ||||||||||||
| 5–9 | 150.0 | 102.5 | 118.1 | 121.8 | 112.0 | 135.5 | 141.1 | 109.6 | 121.3 | 97.8 | 95.9 | 109.7 |
|
| ||||||||||||
| 10–14 | 117.7 | 141.3 | 140.5 | 157.7 | 131.1 | 134.5 | 122.0 | 127.1 | 112.9 | 127.9 | 139.0 | 108.1 |
|
| ||||||||||||
| Region | ||||||||||||
|
| ||||||||||||
| Atlantic* | 156.1 | 191.1 | 152.1 | 171.0 | 142.4 | 158.8 | 152.1 | 113.2 | 60.4 | 177.6 | 123.1 | 201.4 |
|
| ||||||||||||
| Quebec | 166.4 | 183.3 | 166.1 | 217.2 | 168.1 | 215.6 | 144.0 | 128.0 | 137.5 | 151.0 | 167.8 | 131.0 |
|
| ||||||||||||
| Ontario | 177.9 | 161.3 | 167.8 | 183.6 | 167.8 | 177.3 | 188.6 | 165.5 | 168.5 | 162.7 | 169.8 | 153.1 |
|
| ||||||||||||
| Prairies† | 136.1 | 130.4 | 151.5 | 144.6 | 170.5 | 138.5 | 181.4 | 138.0 | 178.9 | 173.6 | 184.1 | 163.5 |
|
| ||||||||||||
| British Columbia | 199.0 | 142.9 | 113.7 | 120.0 | 79.4 | 176.4 | 158.8 | 191.4 | 130.1 | 108.4 | 133.2 | 113.6 |
|
| ||||||||||||
| Cancer type | ||||||||||||
|
| ||||||||||||
| Leukemia | 48.5 | 45.6 | 50.1 | 52.5 | 46.0 | 53.0 | 58.7 | 47.8 | 56.3 | 49.0 | 59.5 | 49.1 |
|
| ||||||||||||
| Lymphoma | 23.0 | 12.8 | 14.9 | 25.0 | 18.8 | 18.8 | 15.1 | 25.9 | 15.7 | 22.0 | 28.9 | 17.9 |
|
| ||||||||||||
| CNS | 39.5 | 41.4 | 37.3 | 36.8 | 46.6 | 47.1 | 45.5 | 30.2 | 28.9 | 35.4 | 30.2 | 35.3 |
|
| ||||||||||||
| Neuroblastoma | 13.8 | 11.7 | 12.6 | 15.9 | 9.8 | 14.0 | 12.5 | 8.2 | 10.3 | 13.8 | 11.3 | 11.0 |
|
| ||||||||||||
| Retinoblastoma | 2.8 | 1.4 | 1.4 | 2.1 | 1.4 | 6.2 | 1.4 | 4.2 | 3.5 | 2.7 | 4.9 | 3.5 |
|
| ||||||||||||
| Renal tumour | 8.1 | 10.9 | 3.4 | 5.3 | 5.5 | 8.1 | 4.8 | 7.3 | 8.2 | 9.5 | 7.5 | 8.3 |
|
| ||||||||||||
| Hepatic tumour | 4.1 | 4.2 | 4.2 | 5.5 | 4.2 | 4.2 | 2.8 | 2.0 | 6.2 | 2.8 | 4.8 | 3.5 |
|
| ||||||||||||
| Bone tumour | 5.4 | 6.7 | 6.1 | 6.7 | 6.0 | 7.4 | 6.6 | 5.2 | 5.2 | 4.7 | 3.3 | 4.5 |
|
| ||||||||||||
| Soft tissue sarcoma | 8.7 | 9.5 | 14.1 | 14.8 | 8.1 | 4.7 | 7.4 | 10.0 | 9.3 | 5.9 | 11.0 | 8.8 |
|
| ||||||||||||
| Germ cell tumour | 8.2 | 7.6 | 4.8 | 2.1 | 6.1 | 7.5 | 8.6 | 3.5 | 4.7 | 7.4 | 2.6 | 2.7 |
|
| ||||||||||||
| Carcinomas‡ | 3.4 | 6.1 | 5.5 | 6.0 | 4.0 | 2.7 | 7.3 | 6.0 | 4.6 | 4.0 | 0.7 | 2.7 |
|
| ||||||||||||
| Other | 1.3 | 0.7 | 1.4 | 0.7 | 0.0 | 1.4 | 0.0 | 0.0 | 0.0 | 0.7 | 0.0 | 0.7 |
Note: ASIR = age-standardized incidence rate, CNS = central nervous system.
*
Includes Nova Scotia, Prince Edward Island, Newfoundland and Labrador, and New Brunswick.
†
Includes Manitoba, Alberta and Saskatchewan.
‡
Includes adrenocortical carcinoma, thyroid carcinoma, nasopharyngeal carcinoma, malignant melanoma, skin carcinoma, and other and unspecified carcinomas.